Anxiety disorders are the most prevalent mental health conditions in Canada — affecting roughly 1 in 4 Canadians at some point in life, with generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, and specific phobias as the major categories, plus obsessive-compulsive disorder (OCD) historically classified with anxiety disorders (now separately in DSM-5). This article is a Canadian evidence-and-pathway guide to psychedelic-assisted therapy options for anxiety: psilocybin with the strongest published anxiety-specific evidence in cancer-related anxiety and depression (Griffiths 2016; Ross 2016 — same J Psychopharmacology Dec 2016 issue); off-label ketamine with emerging evidence for treatment-resistant anxiety and OCD; Spravato — NOT approved for anxiety disorders; and the SAP-investigational pathways and insurance realities. We also walk through what the evidence does — and does not — show.
Key takeaways
- Anxiety disorders affect ~1 in 4 Canadians lifetime — most prevalent mental health conditions in Canada.
- Psilocybin has the strongest published anxiety-specific evidence in the cancer-related anxiety and depression population: Griffiths et al. 2016 and Ross et al. 2016 (both J Psychopharmacology Dec 2016 issue) showed sustained reductions in anxiety and depression in patients with life-threatening cancer.
- Goodwin 2022 NEJM TRD study showed broader signal in patients with comorbid anxiety symptoms.
- Off-label ketamine for treatment-resistant anxiety and OCD: emerging RCT evidence (Glue 2017 GAD/SAD; Rodriguez 2013 OCD); smaller effect sizes than for TRD.
- Spravato is NOT approved for anxiety disorders. Approved for TRD only — not GAD, panic, social anxiety, or OCD.
- MDMA-AT is NOT approved for anxiety disorders. Investigational for PTSD only.
- First-line treatments — CBT (cognitive behavioural therapy), SSRIs, SNRIs (and ERP [exposure and response prevention] for OCD) — should typically be tried first. Psychedelic-assisted therapy is appropriately considered after first-line trials.
- Insurance: Spravato off-label uses generally NOT covered for anxiety; off-label ketamine generally NOT covered out-of-pocket; psilocybin SAP not covered.
Defining anxiety disorders
DSM-5 anxiety disorders include:
- Generalized anxiety disorder (GAD): excessive worry across multiple domains, ≥6 months
- Panic disorder: recurrent unexpected panic attacks plus persistent concern
- Social anxiety disorder (SAD): marked fear of social/performance situations
- Specific phobia: marked fear of specific object/situation
- Agoraphobia: fear of multiple situations involving difficulty escape
DSM-5 separated:
- Obsessive-compulsive disorder (OCD): now in OCD and Related Disorders chapter
- PTSD: now in Trauma and Stressor-Related Disorders chapter
This article focuses primarily on the DSM-5 anxiety disorders and OCD. PTSD is addressed in PTSD and Psychedelic-Assisted Therapy. End-of-life distress (often involving anxiety) is in End-of-Life Distress and Psychedelic-Assisted Therapy.
The anxiety evidence map for psychedelic-assisted therapy
Psilocybin — cancer-related anxiety/depression strongest evidence
- Griffiths RR, Johnson MW, Carducci MA, et al. 2016 — J Psychopharmacol 30(12):1181-1197. Single high-dose psilocybin in life-threatening cancer patients with anxiety/depression; sustained reductions across 6-month follow-up.
- Ross S, Bossis A, Guss J, et al. 2016 — J Psychopharmacol 30(12):1165-1180. Parallel NYU trial; similar findings of sustained anxiety/depression reduction.
- Long-term follow-up data (Agin-Liebes 2020) showed sustained effects out to 4.5 years.
- Goodwin 2022 NEJM COMP001 TRD trial: broader signal in patients with comorbid anxiety; not specifically anxiety-disorder primary.
- Carhart-Harris 2021 NEJM: psilocybin vs escitalopram in MDD — anxiety as secondary outcome.
Off-label ketamine for anxiety / OCD
- Glue 2017 GAD/SAD RCT (PMID 28768444): single-dose IV ketamine in patients with treatment-resistant GAD and/or SAD; rapid reduction in anxiety symptoms
- Rodriguez 2013 OCD RCT (PMID 23631729): single-dose IV ketamine in OCD; rapid reduction in obsessive-compulsive symptoms
- Treatment-resistant anxiety / OCD: emerging clinical use particularly in patients who have failed multiple SSRI trials
- Effect sizes smaller than TRD
Spravato — NOT for anxiety disorders
Spravato (esketamine) is Health Canada-approved for treatment-resistant depression (TRD) only. Not approved for GAD, panic disorder, social anxiety, OCD, or other anxiety disorders.
MDMA — NOT for anxiety disorders
MDMA-AT investigational for PTSD only. Not approved for anxiety disorders or OCD.
For more detail see Psilocybin for Anxiety and Depression, Ketamine Therapy for OCD, and the Ketamine Therapy in Canada guide.
Decision framework — comparing anxiety options
| Factor | Psilocybin (SAP) | Off-label ketamine | Spravato | First-line (CBT, SSRI) |
|---|---|---|---|---|
| Health Canada approval | No (SAP investigational) | No (off-label; med approved as anaesthetic) | No for anxiety (TRD only) | Yes (depending on indication) |
| Strongest anxiety-specific evidence | Cancer-related anxiety (Griffiths/Ross 2016) | GAD/SAD (Glue 2017); OCD (Rodriguez 2013) | TRD only | Substantial first-line RCT base |
| Insurance coverage | No | Generally no | TRD only | Provincial drug plans (SSRI) |
| Sessions to evaluate | 1-2 dosing sessions | 4-6 sessions typical | TRD only | Weeks to months |
| Psychotherapy | Always required (preparation + integration) | Variable | No (label) | CBT primary modality |
Canadian access pathways
Civilian anxiety / OCD
- CBT and SSRI first-line: most provinces have publicly funded mental health programs; private psychotherapists; provincial drug plans cover most SSRIs
- Off-label ketamine for treatment-resistant anxiety: out-of-pocket dominantly; ~$400–$1,500/session
- Psilocybin SAP: case-by-case Health Canada approval; minimal coverage; smaller capacity for anxiety-disorder primary indications than for end-of-life distress
Veterans (VAC)
- Anxiety disorders may be service-related; VAC pathway depends on specific condition documentation
- Ketamine therapy: established case-by-case for service-related anxiety/OCD with supporting documentation
- Psilocybin: not covered
Workers' compensation
- Anxiety/OCD may be compensable depending on workplace exposure and provincial framework
- WSIB Ontario, WCB Alberta: case-by-case for compensable cases
What the evidence does NOT say
- No psychedelic-assisted therapy is approved for anxiety disorders in Canada.
- Psilocybin's anxiety evidence is concentrated in the cancer/end-of-life population. Generalization to non-cancer anxiety populations is supported by mechanism but not by phase 3 anxiety-specific trials.
- Ketamine's anxiety effect sizes are smaller than for TRD. Glue 2017 and Rodriguez 2013 showed signal but smaller than the TRD evidence base.
- First-line treatments — CBT, exposure-based protocols (ERP for OCD), SSRIs, SNRIs — should typically be tried first. Psychedelic-assisted therapy is appropriately considered after first-line trials have not produced adequate response.
- Safety considerations: Psilocybin requires comprehensive screening for psychotic-disorder personal/family history. Ketamine cardiovascular and dissociation effects. Pre-existing severe anxiety can paradoxically worsen with psychedelic experience without adequate preparation.
How ATMA CENA works with anxiety / OCD patients
- Comprehensive intake: anxiety/OCD history, prior treatments (CBT, ERP, SSRI, SNRI), comorbid conditions, screening for psychotic-disorder risk
- Three-phase model: preparation + dosing + integration — particularly important for anxiety populations given preparation reduces anticipatory anxiety
- coordinated care: anxiety-specialty therapist or CBT/ERP therapist remains primary
- Honest framing: ATMA CENA will route patients to first-line evidence-based treatments before psychedelic-assisted therapy where clinically appropriate
For more detail see Psilocybin for Anxiety and Depression and Ketamine Therapy for OCD.
Frequently asked questions
Are psychedelic-assisted therapies approved for anxiety in Canada? No. No psychedelic-assisted therapy is Health Canada-approved for anxiety disorders. Spravato is approved for TRD only — not for anxiety disorders. Off-label ketamine and psilocybin SAP are investigational for anxiety populations.
What's the strongest psilocybin anxiety evidence? The Griffiths 2016 and Ross 2016 trials in J Psychopharmacology December 2016 issue — both in cancer-related anxiety and depression populations. Long-term follow-up (Agin-Liebes 2020) showed sustained effects.
Does psilocybin work for non-cancer anxiety? The published psilocybin anxiety evidence is concentrated in cancer-related populations. Mechanism-based generalization is supported but not by phase 3 non-cancer anxiety RCTs. Goodwin 2022 NEJM TRD trial showed signal in patients with comorbid anxiety symptoms.
What about ketamine for OCD? Rodriguez 2013 RCT showed rapid reduction in obsessive-compulsive symptoms with single-dose IV ketamine. Effect sizes smaller than TRD evidence; sustained-effect data more limited.
What about ketamine for GAD or social anxiety? Glue 2017 RCT showed signal for treatment-resistant GAD/SAD with single-dose IV ketamine. Real-world clinical use is increasing for treatment-resistant cases.
Should I try first-line treatments first? Generally yes. CBT (for anxiety, panic, social anxiety, OCD-ERP for OCD) and SSRIs/SNRIs are first-line evidence-based treatments. Psychedelic-assisted therapy is typically appropriate after first-line trials have not produced adequate response.
What's the cost of psychedelic-assisted therapy for anxiety?
- Off-label IV ketamine: ~$500–$1,500/session
- Off-label IM/SL ketamine: ~$400–$900/session
- Psilocybin SAP: variable; supply via Filament Health no-charge SAP option exists; clinical hours separate
- Insurance coverage for these uses is generally not available for anxiety disorders.
Is anxiety from cancer treatment different? Yes. Cancer-related anxiety / existential distress is the population with the strongest psilocybin evidence. See End-of-Life Distress and Psychedelic-Assisted Therapy.
Can people with severe anxiety have a psychedelic experience? Severe pre-existing anxiety can paradoxically worsen with psychedelic experience without adequate preparation. Comprehensive intake, screening, and substantial preparation phase are critical for safety and outcomes.
What about Spravato off-label for anxiety? Off-label use is at clinical discretion within Canadian prescribing principles. Insurance coverage is limited to label indications (TRD). Off-label use for anxiety disorders is rarely the appropriate first choice given absence of approved indication.
Sources
- Griffiths RR, Johnson MW, Carducci MA, et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol, 30(12):1181-1197. PMID: 27909164.
- Ross S, Bossis A, Guss J, et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol, 30(12):1165-1180. PMID: 27909165.
- Agin-Liebes GI, Malone T, Yalch MM, et al. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol, 34(2):155-166. PMID: 31916890.
- Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
- Glue P, Medlicott NJ, Harland S, et al. (2017). Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol, 31(10):1302-1305. PMID: 28768444.
- Rodriguez CI, Kegeles LS, Levinson A, et al. (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology, 38(12):2475-83. PMID: 23631729.
- Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
- Health Canada — Spravato Notice of Compliance and Product Monograph: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
- Public Health Agency of Canada — Mental Illness Surveillance: https://health-infobase.canada.ca/mental-illness/
- CANMAT 2018 Anxiety Disorders Guidelines: https://www.canmat.org/
- International OCD Foundation — Treatment guidelines: https://iocdf.org/about-ocd/treatment/
- Carhart-Harris R, Giribaldi B, Watts R, et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15):1402-1411. PMID: 33852780.
Related articles
- Psilocybin for Anxiety and Depression
- Ketamine Therapy for OCD
- End-of-Life Distress and Psychedelic-Assisted Therapy
- PTSD and Psychedelic-Assisted Therapy
- Treatment-Resistant Depression and Psychedelic-Assisted Therapy
- Psilocybin Therapy in Canada
- Ketamine Therapy in Canada
- Insurance Coverage for Psychedelic-Assisted Therapy in Canada
Last updated: 2026-05-06